As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
|Articles|October 5, 2015
FDA Revokes Approval of Sun Pharma Antiseizure Drug
October 5, 2015.
Advertisement
FDA has revoked its March approval of Sun Pharma’s Elepsia XR antiseizure medication, writes
The Agency has cited manufacturing quality problems at the Halol, India, facility where Elepsia is produced as the reason for revoking the drug. According to FDA, the compliance status of the Halol facility was not accurately displayed, resulting in the erroneous approval of the NDA.
The revocation is the latest in a series of cGMP issues that have dogged Sun Pharma's Halol facility, including the recall this year of Sun's itbupropion hydrochloride tablets and its eye solutions.
Advertisement
Related to this article
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
2
The Unmet Needs That Will Define the Next Generation of GLP 1s: Q&A with Dr. Bo Liang
3
Viatris Acquires Pacira BioSciences for $1.65 Billion
4
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
5